WayPath is a development-stage biopharmaceutical company founded in 2019 and led by two Louisiana State University oncology researchers with over 50 years of combined scientific expertise.
WayPath holds exclusive license and commercialization rights from LSU for over 300 variants of its lead compound, PP1. A first-in-class BBB-crossing metabolic compound targeting glioblastoma and canine cancer via mitochondrial respiration blockade.
6M new cancer diagnoses for canines each year
1 in 4 canines will be diagnosed with cancer
Dr. Reiss is the Director of Neurological Cancer Research at LSU Health Sciences Center, School of Medicine. With over 25 years in molecular and cell biology and more than 165 peer-reviewed publications, he is a leading authority in oncology research.
Dr. Jursic is a Professor of Medicinal Chemistry at the University of New Orleans, with over 25 years as a synthetic medicinal chemist specializing in natural product synthesis, heterocyclic chemistry, and computational methodology.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.